Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1968 Jul 27;99(4):184–186.

Eleven-year follow-up of a patient with malignant hypertension secondary to pyelonephritis and renal insufficiency.

T Mawar, J M Rojo-Ortega, J Genest
PMCID: PMC1924322  PMID: 5673225

Full text

PDF
184

Images in this article

185Fig. 1a and 1b
on p.185
185Fig. 2
on p.185

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dollery C. T. Treatment of malignant hypertension. Mod Treat. 1966 Jan;3(1):39–49. [PubMed] [Google Scholar]
  2. HARINGTON M., KINCAID-SMITH P., McMICHAEL J. Results of treatment in malignant hypertension: a seven-year experience in 94 cases. Br Med J. 1959 Nov 14;2(5158):969–980. doi: 10.1136/bmj.2.5158.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. MOYER J. H., HEIDER C., PEVEY K., FORD R. V. The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med. 1958 Feb;24(2):177–192. doi: 10.1016/0002-9343(58)90306-1. [DOI] [PubMed] [Google Scholar]
  4. McCORMACK L. J., BELAND J. E., SCHNECKLOTH R. E., CORCORAN A. C. Effects of antihypertensive treatment on the evolution of the renal lesions in malignant nephrosclerosis. Am J Pathol. 1958 Nov-Dec;34(6):1011–1021. [PMC free article] [PubMed] [Google Scholar]
  5. Sokolow M., Perloff D. The choice of drugs and the management of essential hypertension. Prog Cardiovasc Dis. 1965 Nov;8(3):253–277. doi: 10.1016/s0033-0620(65)80018-4. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES